TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

Clinical trial NCT06485466 · RECRUITING

Trial details

NCT number: NCT06485466
Sponsor: Guohui Xu
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Unresectable Hepatocellular Carcinoma Transarterial Chemoembolization Camrelizumab Apatinib

Start date: 2024-08-10
Primary completion: 2026-06-30
Enrollment: 101

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.